In recent years there has been much interest in the fibrinolytic enzyme system, in large part stimulated by the availability of fibrinolytic enzymes for therapeutic trial. There has been a limited interest in fibrinolysis over the last thirty years, but as so often happens no great general attention was paid to this aspect of research until it emerged that the fibrinolytic enzyme system could be exploited to remove intravascular deposits of fibrin. It must be made clear from the outset that it is unlikely that thrombolytic enzymes will solve the numerous problems associated with the intravascular deposition of fibrin and that this treatment is still in the clinical investigative stage. The present indications for the use of fibrinolytic agents are strictly limited. Observations in patients given such enzymes have, however, greatly increased understanding of the physiology and pathology of the fibrinolytic enzyme system and it may be that from such work will arise the possibility of prophylaxis of thrombosis rather than its treatment when established. There is evidence that the system is constantly active under physiological circumstances and it may be that the important therapeutic goal will be the discovery of an agent capable of increasing the normal background of physiological fibrinolytic activity. Components Though of great complexity, the fibrinolytic system has four main components-plasminogen, plasmin, activators and inhibitors. Plasminogen and plasmin: Plasminogen is a plasma globulin, inactive until converted by activators to plasmin, a proteolytic enzyme with wide substrate specificity. Plasmin has as much affinity for fibrinogen as for fibrin when tested in vitro (Ratnoff 1953) , but substrate specificity for fibrin is conferred in vivo. Plasmin will, however, digest other plasma proteins, in particular other coagulation factors (e.g. the components of blood thromboplastin). In addition, plasmin will digest casein and caseinolytic assay of plasmin is an important technique in fibrinolytic studies. Plasminogen can be assayed by adding an excess of activator and measuring the resulting plasmin (Remmert & Cohen 1949) .
Activators ofplasminogen: Activators are present in almost all body tissues and are found in especially high concentrations in prostate, thyroid, lungs and uterus (Albrechtsen 1957). Plasma plasminogen activator, which is present in trace amounts in normal plasma, is found in increased amount after exercise, and after injection of adrenaline, pyrogens, nicotinic acid and other non-enzymatic agents. One site of production of plasma activator is probably the walls of veins with local anoxia as an important stimulus (Kwaan & McFadzean 1956 , Todd 1959 .
Other activators of current interest are urokinase, streptokinase and staphylokinase. Streptokinase is produced by the hoemolytic streptococcus and was the first activator to be identified (Tillett & Garner 1933) . Urokinase is the physiological plasminogen activator present in normal urine and may represent, in part at least, excreted plasma activator. Plasmin once produced in small amounts from plasminogen can, by an autocatalytic effect, activate more plasminogen.
The measurement of activators is an important aspect of laboratory studies on fibrinolysis. Unfortunately, rapid simple assay systems are not available. The plasminogen-enriched '311-labelled clot system is excellent as a research method but is too complex for routine control of thrombolytic therapy. In this technique fibrinogen is tracelabelled with 1311, enriched with plasminogen and clotted round a wire spiral. Activator is measured by the release of radioactivity ). The fibrin plate assay also measures the ability to lyse fibrin, but it requires overnight incubation and so is unsuitable for concurrent control of therapy; the area of lysis on the plate is measured. The euglobulin lysis technique is primarily sensitive to activator but is also dependent on plasminogen and fibrinogen levels. When plasminogen has been depleted by recent administration of activator, euglobulin lysis times may be long, even in the presence of high concentrations of activator. Despite these recognized limitations the euglobulin lysis time is the best available simple test system for activator; the principle of the euglobulin lysis method is the removal of inhibitors. The details of the methods used by the authors in the study of fibrinolysis have recently been described .
Inhibitors: There is a powerful plasma antiplasmin with two components, one of which becomes effective quickly and the other much more slowly.
Physiological Role ofthe Fibrinolytic Enzyme System
It is probable that the system has a physiological role in maintaining the patency of the vascular tree by promoting the lysis of intravascular fibrin. There is evidence that the system is constantly active under physiological circumstances. There is reasonable evidence that the low levels of fibrinolytic activity seen in normal unstressed adults are due to the presence of smaUl amounts of plasminogen activator in the circulation and it has also been shown that the increased levels of fibrinolytic activity seen after exercise are due to plasminogen activator. The widespread occurrence of plasminogen activator in the tissues also suggests that the fibrinolytic system has a role in removing fibrin when it is no longer needed in processes ofrepair in the tissues.
Sherry and his associates in St Louis have provided a reasonable hypothesis for the mechanism of clot lysis in vivo . According to this, plasma and any thrombi in the vascular system respond differently to circulating activator. In plasma, activator converts plasminogen to plasmin, but provided plasminogen conversion is not excessively rapid, antiplasmin neutralizes the plasmin produced and in consequence there is no free proteolytic activity in the circulation. In thrombi, on the other hand, where effective antiplasmin concentrations are said to be relatively low, plasminogen activator diffuses into the thrombus and activates plasminogen in close association with fibrin, which is digested. In this way substrate specificity is conferred on plasmin in vivo and the term thrombolysis is applied to the whole mechanism whereby preformed thrombi are lysed in vivo. Plasminogen has a strong affinity for fibrinogen and fibrin and so in normal circumstances thrombi have a high plasminogen content. The hypothesis is also supported by the fact that in vitro, using clots tagged with radioactive iodine and enriched with plasminogen, lysis is readily produced by activator in the surrounding medium and lytic activity is a function of the concentration of clot plasminogen. Such clots, however, are very resistant to lysis by plasmin in the medium and it would seem that the function of plasma plasminogen is to endow any clots which may form, whether in an intravascular or extravascular site, with the capacity to mediate their subsequent lysis. In this way clot lysis is mediated without the appearance of free plasmin in the circulation with its attendant hazards of depletion of fibrinogen and defective fibrin polymerization. As a consequence of defective fibrin polymerization there results a prolonged whole-blood clotting time, prolonged one-stage prothrombin time and thrombin time, and such clots as form are friable and more than usually susceptible to lysis. Assays for coagulation factors may give falsely low values. When there is excess free plasmin in the circulation, it not only interferes with hamostasis by means of defective fibrin polymerization, but also there is evidence, despite the assay distortion, that the free plasmin digests other coagulation factors, in particular factor V, factor VIII (antihimophilic globulin) and prothrombin . Defective fibrin polymerization, depletion of coagulation factors and accelerated clot lysis all contribute to the himorrhagic state which is a hazard of administration of potent thrombolytic enzymes.
The folUowing brief review of the agents available for therapy indicates why streptokinase has been the agent most extensively used in clinical trial.
Agents Availablefor Thrombolytic Therapy Activator or plasmin: In a consideration of the available materials for thrombolytic therapy, one of the most controversial areas is whether it is more rational to use activators or preformed plasmin as a therapeutic agent.
The evidence suggests that the use of activators is to be preferred. It would seem likely, as indicated previously, that the mechanism of fibrinolysis in vivo is the diffusion of activator into thrombus with activation of intrinsic clot plasminogen in close association with fibrin, the substrate of choice, which is digested.
Evidence of the importance of activation of intrinsic clot plasminogen is provided by the fact that rates of lysis of preformed radioactive clots are dependent on their plasminogen content. Working 'in vitro', when radioactive clots are placed in plasma, the lytic activity of urokinase, streptokinase and plasmin can be compared with the coagulation defect produced by each of these agents. Urokinase and streptokinase can cause rapid thrombolysis with no effect on the thrombin time or prothrombin time. However, plasmin added to the same test system may give no thrombolytic effect but produces marked prolongation of the thrombin time and prothrombin time, i.e. there is a profound polymerization defect (McNicol & Douglas 1964, unpublished) . It would seem likely that the infusion of plasmin would produce a life-threatening coagulation defect before any appreciable thrombolytic effect.
No clinical proof of this concept is available because in fact the so-called plasmin preparations which are commercially available owe the great part of their fibrinolytic activity to their content of streptokinase. The plasmin content of an ampoule of one such preparation is neutralized by a few millilitres of plasma and the fibrinolytic activity of the preparation is almost entirely due to its streptokinase content (Sawyer et al. 1961 ). There are widely differing levels of streptokinase antibodies in the population, depending for example when the individual had a streptococcal throat infection. Streptokinase will not produce its particular biochemical effects until sufficient has been given to neutralize circulating streptococcal antibody. If preparations of this type (i.e. streptokinase-plasmin mixtures) are to be used then, as with streptokinase, it is essential to calculate an initial antibody neutralizing dose for each patient. Otherwise no biochemical effect will be produced in a substantial proportion of subjects.
Urokinase is a human protein and is almost certainly not antigenic. Compared with streptokinase it is relatively non-toxic. On the other hand, at the moment it is very expensive, though when manufactured in bulk the price may be substantially reduced; bearing in mind the source of the material (human urine), and the purification necessary, it is unlikely ever to be cheap. The preparation available at the present time in this country is not homogeneous and both in vivo (in small dosage) and in vitro has shown coagulative activity; test systems using Hageman plasma have been the most sensitive for the demonstration of this coagulative effect but this has also been shown using normal plasma. There is thromboplastic activity in human urine. Whether the coagulative activity of the urokinase preparation is due to contamination with this thromboplastic activity, or whether this is a property of the urokinase molecule, is not certain. In practical therapeutics there may concurrently be so much lytic activity that this coagulative property does not matter, but the clinician would use it with more confidence if it were a pure protein. The authors have used urokinase in large dosage (1,250,000 units over forty-eight hours). There was no shortening of the recalcification times and no increased ability to shorten the coagulative time of Hageman plasma. The interpretation of this, however, is difficult because there was a minor polymerization defect and therefore inevitable distortion of the assay system. Following infusion of urokinase there is a rise in activator level in the blood with a fall in plasminogen and some fall in fibrinogen concentration (McNicol, Gale & Douglas 1963 ).
Johnson and his associates (1963) have studied the biochemical changes following urokinase infusion. They report that although there is a plasma inhibitor a single priming dose and a uniform sustaining dose have been established; when these optimal doses were infused the plasminogen level was not so markedly reduced as with streptokinase, while a thrombolytic level of activator was sustained. The role of urokinase as a clinically effective thrombolytic enzyme has still to be proved, but convincing photographic evidence has been produced of its use in the treatment of haemorrhage into the anterior chamber of the eye.
Streptokinase, the first plasminogen activator to have become available, is still the most widely used. It is expensive and antigenic. Antibodies to streptokinase are distributed throughout the population, varying very widely in concentration, and until enough streptokinase has been given to neutralize circulating antibody, the specific biochemical effect on the fibrinolytic enzyme system is not seen. For this reason, when using streptokinase for systemic therapy it is essential to calculate an individual antibody neutralizing dose for each patient.
Because streptokinase is antigenic the antibody levels rise very markedly following infusion, so that the patient is resistant to this therapy at least for many months thereafter. Streptokinase preparations at present are somewhat impure and tend to induce fever and there are difficulties in the control of systemic therapy, although it is probable more simple measures suffice for the control of regional perfusion. The biochemical effects following streptokinase infusion include rise in level of activator, fall in plasminogen and fibrinogen concentration, prolongation of the prothrombin time and recalcification time and a fall in the concentrations of prothrombin, factor V and factor VIII (antihaemophilic globulin) . It is of importance to appreciate that during the phase of total plasminogen depletion any fibrin laid down is unlysable and rethrombosis at this stage results in a thrombus which cannot be removed by lytic enzymes.
Minor degrees of fever are common after giving streptokinase; occasionally this may be alarming. In one patient studied, there was recrudescence of fever ten days later, for which no other clinical explanation was apparent. There was at the same time a rise in the eosinophil count, and this may represent a sensitization phenomenonanalogous to serum sickness. There is reasonable clinical evidence that pyrexial reactions to streptokinase can be prevented in whole or in part by the previous administration of steroid.
Non-enzymatic agents: A number of nonenzymatic agents, when administered parenterally, induce a fibrinolytic response. Of three substances used for this puipose, adrenaline, nicotinic acid and pyrogens, the most promising has been nicotinic acid; but for many hours after a first injection there is resistance to subsequent injections, even in increased dosage; in consequence, no sustained thrombolytic effect can be achieved and there are troublesome sideeffectsflushing of the skin and hypotension.
In pharmacological studies androgens and chlorpropamide have been shown to cause increased fibrinolytic activity (Fearnley et al. 1960 , Fearnley & Chakrabarti 1962 . Von Kaulla (1963) has made a particular study of the problem of pharmacological activators; one of the most active compounds studied by him has been para-iodobenzoate. Pharmacological activators may yet be found to have a role in the prophylaxis of thrombosis by increasing background fibrinolytic activity. The levels of activity attained by currently available pharmacological agents is very small in comparison with that induced by infusing streptokinase.
Current Role ofThrombolytic Enzymes in

Clinical Medicine
It should be clear that thrombolytic therapy is still a long way from routine clinical practice. The possibility of removing intravascular fibrin, by enzymatic rather than mechanical means, is attractive. Thrombolytic therapy has the theoretical advantage of removing fibrin in small vessels beyond the reach of the surgeon. The basis for believing that thrombolytic therapy is a practical clinical possibility depends on the human forearm vein experiments of Johnson and his associates (Johnson & McCarty 1959 , Johnson et al. 1963 ), on individual welldocumented cases and on a small number of controlled clinical trials.
Humanforearm vein experiments: Venous thrombi were produced in human volunteers by mechanical and chemical injury to t-he intima (Johnson & McCarty 1959 , Johnson et al. 1963 . The position and the size of the thrombi were estimated by clinical observation and by venography and the volunteers were given systemic infusions of streptokinase (in differing dosage level) and of urokinase. The value of the therapy was judged by the ability to produce lysis of thrombus and to prevent reformation. No lysis was found in controls but high and intermediate dosages of streptokinase were found to be very effective, as was urokinase. When there was reformation of thrombus at the time of total plasminogen depletion by streptokinase, the newly deposited fibrin was unlysable.
Individual well-studied patients showing angiographic proof of vascular clearing have also provided evidence of the potential of this therapy (Cotton etal. 1962 , Verstraete et al. 1963 , McNicol, Reid, Bain & Douglas 1963 . Though vascular clearing may be effected, distal tissue necrosis may have resulted before this has been achieved; it is obviously important to treat such patients as early as possible after vascular occlusion has occurred. To clear limb vessels may require the streptokinase infusion to be continued for thirty to sixty hours or longer. The authors have succeeded in clearing limb arteries by local intraarterial perfusion of streptokinase, supplied through a polythene catheter to the site of the obstruction (McNicol, Reid, Bain & Douglas 1963) . When vascular clearing has been accomplished and streptokinase discontinued, full heparinization by continuous infusion should be maintained for forty-eight hours while an oral anticoagulant drug effect is being induced.
The role of this therapy must ultimately depend on the result of well-controlled clinical trial. A start has been made by Fletcher and his associates , Fletcher, Sherry, Alkjaersig, Smymiotes & Jick 1959 ) who report their findings in a small number of patients. They established that this type of treatment was possible in patients with myocardial infarction, pulmonary embolism and venous thrombosis. They found no increased risk of pulmonary embolism in patients with venous thrombosis treated with streptokinase. The streptokinase was given as an initial individually titrated dose plus a sustaining infusion; in a very small series of patients with myocardial infarction allocated at random to treatment with or without streptokinase, the difference could have arisen by chance in only one such trial in five. Dewar et al. (1963) failed to find a benefit in the treatment of myocardial infarction using streptokinase-plasmin mixture, but no individual initiating dose was calculated and there must therefore be some doubt as to whether an adequate biochemical change had been induced in all their patients.
Patients to be Consideredfor Thrombolytic Therapy Theoretically, intravascular fibrin deposition in any site might be amenable to therapy. Until more knowledge is gained therapy should only be considered in certain cases of massive pulmonary embolism and of occlusion of major limb arteries.
Pulmonary embolism: The majority of patients should be treated as formerly with heparin and oral anticoagulant drttgs. When, however, the embolism is believed to be massive and the patient critically ill with severe dyspncea, raised jugular venous pressure and arterial hypotension, then systemic streptokinase infusion with large dosage should be used.
Major limb artery occlusion: The surgeon should explore the site of the block and remove the arterial obstruction if this is possible. If surgical clearance cannot be attained then the artery is closed with a catheter left in position, through which streptokinase is pumped to the proximal end of the obstruction. Numerous aspects must be considered before deciding to use streptokinase; these include the general fitness of the patient, the viability of the limb, the health of the vessel wall and the age of the thrombus. The patient should be sufficiently fit to withstand the possible toxic effects (pyrexia and vomiting) of streptokinase. If the limb is considered to be viable despite the arterial occlusion, then lytic therapy is generally not used; if it is considered, however, that viability is dependent on restoration of flow then thrombolytic enzymes may well be indicated. The case for streptokinase clearing of the vessel is stronger if it is known that the vessel is healthy. It is generally believed that the younger the thrombus the more susceptible it is to lysis.
Control ofthe Hamostatic Defect As described earlier, thrombolytic enzymes in high dosage carry a significant risk of generalized failure of haemostasis. Contraindications to the use of this therapy include ulcerative lesions of the alimentary tract and previous cerebrovascular incidents.
The antidote, in the face of life-threatening hkmorrhage during thrombolytic therapy, is E-aminocaproic acid (EACA). This is a powerful synthetic inhibitor of plasminogen activation. Any fibrin deposited in an intravascular site while EACA is in circulation will have this incorporated and will therefore be resistant to lysis by physiological or therapeutic activators.
Laboratory Control
At the present time a streptokinase infusion is a major laboratory undertaking; with the accumulation of laboratory and clinical experience it may yet be possible to reduce the laboratory monitoring.
The essential measures for laboratory control of streptokinase therapy by regional perfusion at the present time include estimation of an initial antibody neutralizing dose and then control of the subsequent infusion with the euglobulin lysis time and the thrombin clotting time. The infusion rate should be controlled at a level large enough to accelerate euglobulin lysis but not to prolong the thrombin time by more than five seconds. If possible, of course, fibrinogen and plasminogen assays should be carried out to extend understanding of the biochemical changes produced. A dosage rate which produces significant fibrinolytic activity in the circulation will almost certainly produce intense activity in the perfused limb. While further experience may show that it is not necessary to administer an initial antibody neutralizing dose when streptokinase is being given by local perfusion, it is the present view that in the meantime, to be certain of inducing a thrombolytic state, an antibody neutralizing dose should be given over one or two hours.
For systemic infusion an antibody neutralizing dose should be calculated and given over thirty minutes. Thereafter an infusion rate of 50,000-100,000 units of streptokinase per hour should be sustained and the effect followed by the euglobulin lysis time, thrombin clotting time, plasminogen and fibrinogen assays.
The details of these methods and their application in thrombolytic therapy have recently been described by the authors .
Conclusions
Most of the preceding account of the practical details of current thrombolytic therapy has been concerned with streptokinase because this is the activator that has been most widely used. It may be, however, that the next few years will see urokinase replacing streptokinase as the enzyme of choice.
In conclusion, the current problems in thrombo-lytic therapy can be reviewed. The first and most: important is, of course, the lack of an ideal' fibrinolytic agent and the cost or toxicity, or both,. of the agents that are available. Laboratory control of therapy still presents a major problem, particularly of systemic therapy. The evidenco suggests that if streptokinase is given by local perfusion, simplified measures of control are adequate. Finally, of course, there is the formidable problem of demonstrating clinical efficacy. An important point here is case selection. Because of the speed of tissue death subsequent to vascular occlusion, in addition to all the other problems already discussed, it is unlikely that this therapy will ever have widespread application. In carefully selected patients, however, it may well make a useful contribution. It is probable that during the next few years the place of this therapy will become more clearly defined. It will be a great mistake if it becomes widely applied without more objective assessment and without adequate laboratory monitoring. Angiography has been used as the best available objective assessmenteventually properly constructed clinical trial will be required. As mentioned in the introduction, the importance of the fibrinolytic system may yet be found in the aetiology of thrombus or atheroma or in the discovery of a pharmacological agent that will increase background fibrinolytic activity and can be used as a prophylactic against thrombosis in patients at risk.
